Johnson Fistel Files Class Action Suit against TG Therapeutics, Inc.

The complaint alleges that during the Class Period, defendants made false and misleading statements and/or failed to disclose adverse information regarding TG’s business and prospects. Specifically, the complaint alleges defendants failed to disclose that TG was involved in cleaning the data collected in the UNITY-CLL Trial and, as a result, was able to gain an understanding as to the efficacy of the combination therapy; that, as a result of that data cleaning, TG knew the UNITY-CLL Trial had failed to meet its stated goal, and that, as a result, the Company would not be able to seek accelerated approval; and that, given that the UNITY-CLL Trial had failed to meet its stated goal, it was highly unlikely that the combination therapy would meet its primary endpoint of increased progression free survival – in other words, the drug therapy had failed. As a result of defendants’ false statements and/or omissions, the price of TG common stock was artificially inflated during the Class Period to as high as $14.70 per share.

Leave a Reply

Your email address will not be published. Required fields are marked *